|
[Related PubMed/MEDLINE]
Total Number of Papers: 41
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: RZV |
| Long Form |
: recombinant zoster vaccine |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49year old patients. |
HZ, PRISMA-P, SAEs |
| 2 |
2020 |
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. |
HZ, pIMDs, SAEs |
| 3 |
2020 |
Emerging Topics in Vaccine Therapeutics for Adolescents and Adults: An Update for Immunizing Pharmacists. |
CDC/ACIP, FDA, HPV, MMR |
| 4 |
2020 |
Exploring the early phase of implementation of a vaccine-based clinical decision support system in the community pharmacy. |
CDS |
| 5 |
2020 |
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. |
AEs, gE, pIMDs, RT |
| 6 |
2020 |
Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination. |
CMI |
| 7 |
2020 |
Impact of pharmacist intervention on completion of recombinant zoster vaccine series in a community pharmacy. |
OR |
| 8 |
2020 |
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults. |
EQ-5D, PF, QOL, SF-36 |
| 9 |
2020 |
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. |
BI, HZ, IDN, PBDMs, ZVL |
| 10 |
2020 |
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. |
AEs |
| 11 |
2020 |
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology. |
HZ |
| 12 |
2020 |
Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. |
AE, O/E |
| 13 |
2020 |
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine. |
CMI, gE, HZ |
| 14 |
2020 |
The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. |
HZ, PHN, ZVL |
| 15 |
2019 |
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. |
ICER, QALY, ZVL |
| 16 |
2019 |
Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares. |
--- |
| 17 |
2019 |
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. |
QALYs, ZONA, ZVL |
| 18 |
2019 |
Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. |
HZ, ICERs, VVL, VVL |
| 19 |
2019 |
Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65Years and Older. |
HZ, ICER, PHN, QALYs |
| 20 |
2019 |
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. |
HZ, PHN |
| 21 |
2019 |
Evaluation of two frailty indices, with practical application in a vaccine clinical trial. |
FIs, PF, PROs, SF-36 |
| 22 |
2019 |
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. |
AEs, gE, STs, VRRs |
| 23 |
2019 |
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. |
CI, HZ |
| 24 |
2019 |
Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. |
FDA, VAERS |
| 25 |
2019 |
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. |
HZ, ICER, PHN, QALY |
| 26 |
2019 |
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. |
HZ, PHI, PHN, YOA, ZVL |
| 27 |
2019 |
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). |
CI, HSCT, HZ, QOL, VE, ZBPI |
| 28 |
2019 |
Response to: 'Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares' by Didierlaurent et al. |
--- |
| 29 |
2019 |
Risk of gout flares after vaccination: a prospective case cross-over study. |
--- |
| 30 |
2019 |
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. |
AEs, pIMDs, SAEs |
| 31 |
2019 |
The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial. |
Tdap, VRR |
| 32 |
2019 |
The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. |
HZ, NMA, PHN, SAE, VE, ZVL |
| 33 |
2019 |
The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. |
--- |
| 34 |
2019 |
Vaccines for preventing herpes zoster in older adults. |
CI, LZV, NNTB, NNTH, RCTs, RD, RR, VZV |
| 35 |
2019 |
Varicella zoster virus vaccines: an update. |
ACIP, CMI, HZ, VZV, ZVL |
| 36 |
2018 |
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. |
HZ, PHN, YOA, ZVL |
| 37 |
2018 |
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial. |
VRR |
| 38 |
2018 |
Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). |
ACIP, ZVL |
| 39 |
2018 |
Recombinant Zoster Vaccine (Shingrix): A Review in Herpes Zoster. |
HZ, PHN |
| 40 |
2018 |
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. |
ACIP, GSK |
| 41 |
2018 |
The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50Years in Japan: Results of a Markov Model Analysis. |
HZ, PHN, VVL |
|
A Search Service for Abbreviation / Long Form
